|Bid||0.00 x 900|
|Ask||0.00 x 1000|
|Day's range||17.52 - 18.93|
|52-week range||16.37 - 73.03|
|Beta (5Y monthly)||1.91|
|PE ratio (TTM)||N/A|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||49.71|
Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.
If you want to know who really controls Editas Medicine, Inc. ( NASDAQ:EDIT ), then you'll have to look at the makeup...
Shares of Editas Medicine (NASDAQ: EDIT) were tumbling 13% lower this week as of the market close on Thursday, based on data from S&P Global Market Intelligence. Editas Medicine CEO James Mullen specifically mentioned base editing in his comments at the J. P. Morgan conference and seemed a bit defensive.